In this manuscript, we report that CHTM1 is a novel modulator of metabolic stress as its deficiency sensitized human lung cancer cells to metabolic stress-induced cell death mediated by glucose/glutamine deprivation and metformin treatment (Fig. 1). Here, CHCHD5 is linked to lung carcinoma.